PMID- 30519004
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 12
DP  - 2018
TI  - Treatment of relapsed refractory multiple myeloma: which new PI-based combination 
      treatments do patients prefer?
PG  - 2387-2396
LID - 10.2147/PPA.S183187 [doi]
AB  - BACKGROUND AND OBJECTIVES: This study describes preferences of German relapsed 
      refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based 
      combination treatments. METHODS: Patients with a minimum age of 18 years and a 
      diagnosis of RRMM were included. Their preferences were assessed using a discrete 
      choice experiment design, which was developed based on a literature review and 
      two patient focus group discussions. The final discrete choice experiment design 
      consisted of four attributes, namely "therapy application regimen," "time without 
      progression of disease," "possibility of grade >/=3 adverse events (AEs) affecting 
      the blood," and "possibility of grade >/=3 AE heart failure." RESULTS: Analysis was 
      based on 84 patients (36.9% females, mean age 62.7 years, mean multiple myeloma 
      disease duration 5.5 years). Among the tested attributes, "therapy application 
      regimen" was assigned the highest importance for treatment decisions (38.8%), the 
      second important attribute was "time without progression of disease" (38.7%), 
      followed by "possibility of AE heart failure" (13.9%) and "possibility of AEs 
      affecting the blood" (8.6%). Patients preferred oral intake once a day and once a 
      week over other application modes such as oral intake once a day and once a week 
      plus twice-weekly infusions. Furthermore, they preferred longer disease 
      progression-free time and lower risk of grade >/=3 AEs. The highest overall utility 
      was derived for ixazomib + lenalidomide + dexamethasone (utility: 3.218), 
      compared with lenalidomide + dexamethasone (2.769), and carfilzomib + 
      lenalidomide + dexamethasone (1.928). CONCLUSION: RRMM patients prefer treatments 
      with an all-oral application, a longer disease-progression-free time, and a lower 
      probability of AEs. If patients face tradeoffs, they accept a lower 
      progression-free time and/or higher AE rates to get an all-oral therapy.
FAU - Wilke, Thomas
AU  - Wilke T
AD  - Institut fur Pharmakookonomie und Arzneimittellogistik (IPAM), 23966 Wismar, 
      Germany, thomas.wilke@ipam-wismar.de.
FAU - Mueller, Sabrina
AU  - Mueller S
AD  - Ingress-Health, 23966 Wismar, Germany.
FAU - Bauer, Sabine
AU  - Bauer S
AD  - Ingress-Health, 23966 Wismar, Germany.
FAU - Pitura, Silvia
AU  - Pitura S
AD  - Takeda Pharma Vertrieb GmbH & Co. KG, 10117 Berlin, Germany.
FAU - Probst, Leona
AU  - Probst L
AD  - Takeda Pharma Vertrieb GmbH & Co. KG, 10117 Berlin, Germany.
FAU - Ratsch, Boris A
AU  - Ratsch BA
AD  - Takeda Pharma Vertrieb GmbH & Co. KG, 10117 Berlin, Germany.
FAU - Salwender, Hans
AU  - Salwender H
AD  - Asklepios Kliniken Hamburg GmbH, 22763 Hamburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20181109
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC6235009
OTO - NOTNLM
OT  - DCE
OT  - MM patient's treatment preferences
OT  - RRMM
OT  - discrete choice experiment
OT  - relapsed refractory multiple myeloma
COIS- Disclosure TW has received honoraria from several pharmaceutical/consultancy 
      companies, eg, Novo Nordisk, Abbvie; Merck; GSK, BMS, LEO Pharma, Astra Zeneca, 
      Bayer, Boehringer Ingelheim, Pharmerit. SM and SB participated in this study as a 
      staff member of Ingress-health; the work of Ingress-health in this study was 
      sponsored by Takeda Pharma Vertrieb GmbH & Co. KG. SP, LP, and BAR are employees 
      of Takeda Pharma Vertrieb GmbH & Co. KG. HS received consultancy fees, project 
      funding, and reimbursement of travel costs from different pharmaceutical 
      companies, such as Celgene, Janssen-Cilag, Novartis, BMS, Amgen, Takeda. The 
      authors report no other conflicts of interest in this work.
EDAT- 2018/12/07 06:00
MHDA- 2018/12/07 06:01
PMCR- 2018/11/09
CRDT- 2018/12/07 06:00
PHST- 2018/12/07 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2018/12/07 06:01 [medline]
PHST- 2018/11/09 00:00 [pmc-release]
AID - ppa-12-2387 [pii]
AID - 10.2147/PPA.S183187 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2018 Nov 9;12:2387-2396. doi: 10.2147/PPA.S183187. 
      eCollection 2018.